Literature DB >> 2349750

Ascertainment and natural history of treated acromegaly in Northern Ireland.

C M Ritchie1, A B Atkinson, A L Kennedy, A R Lyons, D S Gordon, T Fannin, D R Hadden.   

Abstract

The prevalence of known cases of acromegaly in Northern Ireland in 1984 was 6.3 per 100,000 population. The incidence of newly-diagnosed cases over the preceding 25 years was 5.5 patients per year, or 0.4 patients per 100,000 population per year. This rate would be equivalent to about 200 new cases per year in the United Kingdom. Four options have been available to most of these patients--surgical hypophysectomy (transfrontal or transsphenoidal), pituitary radiotherapy (usually external cobalt beam), drug treatment with bromocriptine, or no treatment. Choice of treatment has been mainly influenced by tumour size, with the larger pituitary adenomas having surgery initially. No single form of treatment has been successful in achieving a clinical remission or cure in more than a minority of cases. The most successful outcome has been where total pituitary ablation has been achieved. Life-table analysis for the whole group shows life expectancy which is not markedly different for that of an age-matched population from Northern Ireland. Morbidity related to long term osteoarthritis and treatment complications remain a major problem. The incidence of malignant tumours is higher than would be expected.

Entities:  

Mesh:

Year:  1990        PMID: 2349750      PMCID: PMC2448267     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN: 0041-6193


  13 in total

1.  Occurrence of cancer in acromegaly and in hypopituitarism.

Authors:  P MUSTACCHI; M B SHIMKIN
Journal:  Cancer       Date:  1957 Jan-Feb       Impact factor: 6.860

2.  Hypophysectomy combined with intrasellar irradiation with yttrium-90.

Authors:  G A EDELSTYN; C A GLEADHILL; A R LYONS; H W RODGERS; A R TAYLOR; R B WELBOURN
Journal:  Lancet       Date:  1958-03-01       Impact factor: 79.321

3.  Effects of L-dopa and chlorpromazine on human growth hormone and TSH secretion in normal subjects and acromegalics.

Authors:  P Singh; D G McDevitt; J Mackay; D R Hadden
Journal:  Horm Res       Date:  1973

4.  Mortality in acromegaly.

Authors:  A D Wright; D M Hill; C Lowy; T R Fraser
Journal:  Q J Med       Date:  1970-01

5.  Epidemiology of acromegaly in the Newcastle region.

Authors:  L Alexander; D Appleton; R Hall; W M Ross; R Wilkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1980-01       Impact factor: 3.478

6.  Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients.

Authors:  H J Quabbe
Journal:  Clin Endocrinol (Oxf)       Date:  1982-02       Impact factor: 3.478

7.  The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours.

Authors:  A Jadresic; L M Banks; D F Child; L Diamant; F H Doyle; T R Fraser; G F Joplin
Journal:  Q J Med       Date:  1982

8.  Conventional supervoltage irradiation is an effective treatment for acromegaly.

Authors:  R C Eastman; P Gorden; J Roth
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

9.  Investigation of the criteria for assessing the outcome of treatment in acromegaly.

Authors:  J Lindholm; B Giwercman; A Giwercman; J Astrup; P Bjerre; N E Skakkebaek
Journal:  Clin Endocrinol (Oxf)       Date:  1987-11       Impact factor: 3.478

10.  Bromocriptine reduces growth hormone in acromegaly.

Authors:  P M Bell; A B Atkinson; D R Hadden; L Kennedy; H Leslie; J D Merrett; B Sheridan
Journal:  Arch Intern Med       Date:  1986-06
View more
  18 in total

Review 1.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

2.  Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features.

Authors:  M Terzolo; C Matrella; A Boccuzzi; S Luceri; M Borriero; G Reimondo; A Pia; E Rovero; P Paccotti; A Angeli
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

3.  Cost of clinical management of acromegaly in Spain.

Authors:  Montse Roset; Sandra Merino-Montero; Manuel Luque-Ramírez; Susan M Webb; Pedro López-Mondéjar; Isabel Salinas; Alfonso Soto; Carmen Bernal; Carlos Villabona; Daniel De Luis; Sergio Donnay; Herminia Pascual; Jesús Pérez-Luis
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

4.  Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

Authors:  I Lancranjan; A B Atkinson
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

5.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.

Authors:  Theodoros Rokkas; Dimitrios Pistiolas; Panos Sechopoulos; Georgios Margantinis; Georgios Koukoulis
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 6.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 7.  Current status and future opportunities for controlling acromegaly.

Authors:  Shlomo Melmed; Mary Lee Vance; Ariel L Barkan; Bengt-Ake Bengtsson; David Kleinberg; Anne Klibanski; Peter J Trainer
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 8.  Oncological complications of excess GH in acromegaly.

Authors:  Susan M Webb; Felipe Casanueva; John A H Wass
Journal:  Pituitary       Date:  2002-01       Impact factor: 4.107

Review 9.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.